Publications by authors named "Kelly Marcom"

Claim this Profile
R
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Neha Pagidipati, Brooke Heidenfelder, Lydia Coulter Kwee, Fatima Rodriguez, Ranee Chatterjee, P Kelly Marcom

Am J Med Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Danielle M File, Yara Abdou, Jeremy Force, Dominic T Moore, Carey K Anders, P Kelly Marcom

Clin Breast Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, P Kelly Marcom

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S Cogan, Vandana G Abramson, P Kelly Marcom

Breast Cancer Res Treat· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, Jodi M Carter, Karthik V Giridhar, P Kelly Marcom

JAMA Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, P Kelly Marcom

Lancet Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, P Kelly Marcom

Nat Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia, P Kelly Marcom

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Kelly Marcom

NPJ Breast Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database.
Timothy J Robinson, Lauren E Wilson, P Kelly Marcom, Melissa Troester, Charles F Lynch

JAMA Netw Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T Dang, P Kelly Marcom

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Sara M Tolaney, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Kelly Marcom

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Costanza Paoletti, Meredith M Regan, Samuel M Niman, Emily M Dolce, Elizabeth P Darga, P Kelly Marcom

NPJ Breast Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis.
Oluwadamilola M Fayanju, Yi Ren, Ilona Stashko, Steve Power, Madeline J Thornton, P Kelly Marcom

Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Project Baseline Health Study: a step towards a broader mission to map human health.
Kristine Arges, Themistocles Assimes, Vikram Bajaj, Suresh Balu, Mustafa R Bashir, Kelly Marcom

NPJ Digit Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, P Kelly Marcom

J Natl Compr Canc Netw· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
John H Strickler, Christel N Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, P Kelly Marcom

BMC Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of treatment on patient-reported distress after breast cancer diagnosis.
Oluwadamilola M Fayanju, Karine Yenokyan, Yi Ren, Benjamin A Goldstein, Ilona Stashko, P Kelly Marcom

Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sara M Tolaney, Hao Guo, Sonia Pernas, William T Barry, Deborah A Dillon, P Kelly Marcom

J Clin Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Jennifer R Bellon, Hao Guo, William T Barry, Chau T Dang, Denise A Yardley, P Kelly Marcom

Breast Cancer Res Treat· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer.
Maciej A Mazurowski, Ashirbani Saha, Michael R Harowicz, Elizabeth Hope Cain, Jeffrey R Marks, P Kelly Marcom

J Magn Reson Imaging· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.
Gayathri R Devi, Holly Hough, Nadine Barrett, Massimo Cristofanilli, Beth Overmoyer, P Kelly Marcom

J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
Matthew P Goetz, William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, P Kelly Marcom

J Natl Compr Canc Netw· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Elizabeth Hope Cain, Ashirbani Saha, Michael R Harowicz, Jeffrey R Marks, P Kelly Marcom

Breast Cancer Res Treat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Jeremy Force, Lynn J Howie, Sara E Abbott, Rex Bentley, P Kelly Marcom

Clin Breast Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis